Biora Therapeutics (BIOR) Stock Price, News & Analysis

Company Overview

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.65 to $0.65
• 50-Day Range: $0.58 to $0.76
• 52-Week Range: $0.48 to $2.71
• Volume: 2,593 shs
• Average Volume: 316,018 shs
• Market Capitalization: $23.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Biora Therapeutics Stock Analysis - MarketRank™

Biora Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 699th out of 1,017 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biora Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biora Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biora Therapeutics are expected to grow in the coming year, from ($1.25) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biora Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biora Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.94% of the float of Biora Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Biora Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Biora Therapeutics has recently increased by 21.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biora Therapeutics does not currently pay a dividend.

Dividend Growth

Biora Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.94% of the float of Biora Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Biora Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Biora Therapeutics has recently increased by 21.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Biora Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biora Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for BIOR on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biora Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

50.97% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BIOR Stock Analysis - Frequently Asked Questions

How have BIOR shares performed this year?

Biora Therapeutics' stock was trading at $1.35 at the beginning of 2024. Since then, BIOR stock has decreased by 51.8% and is now trading at $0.6509.
View the best growth stocks for 2024 here.

How were Biora Therapeutics' earnings last quarter?

Biora Therapeutics, Inc. (NASDAQ:BIOR) posted its earnings results on Monday, August, 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.10. The company earned $0.32 million during the quarter.

When did Biora Therapeutics' stock split?

Shares of Biora Therapeutics reverse split before market open on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Biora Therapeutics?

Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/12/2024
• Today: 9/19/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BIOR
• CUSIP: N/A
• CIK: 1580063
• Web: www.bioratherapeutics.com
• Phone: 833-727-2841
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +2,204.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-124,110,000.00
• Net Margins: N/A
• Pretax Margin: -10,107.33%
• Return on Equity: N/A
• Return on Assets: -228.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.20
• Quick Ratio: 0.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.64) per share
• Price / Book: -0.18

Miscellaneous

• Outstanding Shares: 36,470,000
• Free Float: 17,594,000
• Market Cap: $23.74 million
• Optionable: Optionable
• Beta: 1.24